Citations

Clear

585 citation(s) found for "Tran, Ha".

Cell-Based Therapies in Vascularized Composite Allotransplantation
Mohan, Anita T. , Tran, Duy , Mardini, Samir , Vyas, Krishna S. , Morrison, Shane D.

Mayo Clinic

Journal of Reconstructive Microsurgery | June 26, 2018 | Volume: 34 | Issue: 08 | Pages: 642-650

10.1055/s-0038-1661336 | PMID 29945289 Get It

Background Dendritic cells (DCs) are bone marrow-derived, professional antigen-presenting cells with tolerogenic function. The ability of DCs to regulate alloantigen-specific T cell responses and to promote tolerance has aligned them ideally for a role in vascularized composite allotransplantation (VCA). In this study, we summarize the current evidence for DC therapies for tolerance induction to alleviate the requirement for chronic immunosuppression. Method A comprehensive and structured review of manuscripts published on VCA was performed using the MEDLINE and PubMed databases. All eligible studies published from the year 2000 to 2017 were included in the final results. Result Nineteen original preclinical and clinical studies that employed cell therapy for VCA were included in this review. In vivo DC therapy was found to direct the alloimmune response toward either transplant rejection or tolerance in VCA models. While injection of mature DCs rapidly increases T-cell activity in humans and promotes transplant rejection, the injection of immature DCs acts as an immunosuppressant and inhibits T-cell activity. In addition to immature DCs, mesenchymal stem cells were also found to have a positive effect on allotransplantation of solid organs and bone marrow via cytokine expression which decreases the alloreactive effector lymphocytes and increases CD4+/CD25+/FoxP3 Tregs. Despite the promising findings, the efficacy of cell-based therapies varies greatly across studies, partly due to different methods of cell isolation and purification techniques, source, route and timing of administration, and combination immunosuppressive therapy. Conclusion Additional research is needed to evaluate the efficacy and safety of DC and other cell-based therapeutic measures in human allotransplant recipients. Future direction will focus on the development of novel methods to reduce immunosuppression and develop more individualized management, as well as the clinical application of basic research in the mechanisms of immunologic tolerance.
Lower Fasted‐State but Greater Increase in Muscle Protein Synthesis in Response to Elevated Plasma Amino Acids in Obesity
Tran, Lee , Kras, Katon A., Hoffman, Nyssa, Ravichandran, Jayachandran , Dickinson, Jared M. , D’Lugos, Andrew C. , Carroll, Chad C. , Patel, Shivam H. , Mandarino, Lawrence J. , Roust, Lori R., Katsanos, Christos S. , Katsanos, Christos S , D'Lugos, Andrew C

Mayo Clinic

Obesity | June 13, 2018 | Volume: 26 | Issue: 7 | Pages: 1179-1187

10.1002/oby.22213 | PMID 29896930 Get It

ObjectiveObesity alters protein metabolism in skeletal muscle, but consistent evidence is lacking. This study compared muscle protein synthesis in adults with obesity and in lean controls in the fasted state and during an amino acid infusion.MethodsTen subjects with obesity (age: 36 ± 3 years; BMI: 34 ± 1 kg/m2) and ten controls (age: 35 ± 3 years; BMI: 23 ± 1 kg/m2) received an infusion of L‐[2,3,3,4,5,5,5,6,6,6‐2H10]leucine (0.15 μmol/kg fat‐free mass/min) to measure muscle protein synthesis after an overnight fast and during amino acid infusion.ResultsDespite greater muscle mammalian target of rapamycin phosphorylation (P ≤ 0.05), fasted‐state mixed‐muscle and mitochondrial protein synthesis were lower in subjects with obesity (P ≤ 0.05). However, the change in mixed‐muscle protein synthesis during the amino acid infusion was 2.7‐fold greater in subjects with obesity (P ≤ 0.05), accompanied by a greater change in S6 kinase‐1 phosphorylation (P ≤ 0.05). The change in mitochondrial protein synthesis did not differ between groups (P > 0.05).ConclusionsAdults with obesity have reduced muscle protein synthesis in the fasted state, but this response is compensated for by a greater change in overall muscle protein synthesis during amino acid infusion.
Abstract P-362: PEDIATRIC INTENSIVE CARE PROVIDERS END-OF-LIFE PRACTICES AND ATTITUDES IN VIETNAM
Liu, Juan , Fadadu, Priyal , Kumbamu, Ashok , Schiltz, Brenda , Ouellette, Yves , Xoay, Tran Dang , Phúc, Phan Hữu

Mayo Clinic

Pediatric Critical Care Medicine | May 31, 2018 | Volume: 19 | Issue: 6S | Pages: 157-158

10.1097/01.pcc.0000537819.53549.8c Get It

Abstract P-217: PREVALENCE AND IMPACT OF IMMUNIZATION STATUS ON PICU ADMISSIONS IN HANOI, VIETNAM
Larkin, Soili, Dung, Tran Ba, Ouellette, Yves , Phúc, Phan Hữu

Mayo Clinic

Pediatric Critical Care Medicine | May 31, 2018 | Volume: 19 | Issue: 6S | Pages: 113-113

10.1097/01.pcc.0000537674.76936.a2 Get It

Abstract P-282: SECONDARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS PATIENTS PRESENTING WITH MULTIPLE ORGAN DYSFUNCTION IN A VIETNAMESE PEDIATRIC INTENSIVE CARE UNIT
Galeano, Belinda K. , Ouellette, Yves , Dao, Dyda , Xoay, Tran Dang , Phúc, Phan Hữu

Mayo Clinic

Pediatric Critical Care Medicine | May 31, 2018 | Volume: 19 | Issue: 6S | Pages: 132-133

10.1097/01.pcc.0000537739.27555.5b Get It

Abstract QS22: Breast Implant Infections After First Stage Breast Reconstruction: A Case-Control Study of 272 patients
Banuelos, Joseph, Sabbagh, M. Diya , Roh, Si‐Gyun , Nguyen, Minh-Doan, Tran, Nho V. , Boughey, Judy C. , Sharaf, Basel

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | May 5, 2018 | Volume: 6 | Issue: 4S | Pages: 128-128

10.1097/01.gox.0000534030.98199.a2 Get It

EGFRvIII–Stat5 Signaling Enhances Glioblastoma Cell Migration and Survival
Roos, Alison , Peng, Sen, Inge, Landon J. , Tuncali, Serdar, Pineda, Michael , Millard, Nghia , Mayo, Zachary, Eschbacher, Jennifer , Loftus, Joseph C. , Winkles, Jeffrey A. , Tran, Nhan L. , Pineda, Michael , Winkles, Jeffrey A , Dhruv, Harshil , Tran, Nhan L

Mayo Clinic

Molecular Cancer Research | May 3, 2018 | Volume: 16 | Issue: 7 | Pages: 1185-1195

10.1158/1541-7786.mcr-18-0125 | PMID 29724813 Get It

Abstract Glioblastoma multiforme (GBM) is the most common brain malignancies in adults. Most GBM patients succumb to the disease less than 1 year after diagnosis due to the highly invasive nature of the tumor, which prevents complete surgical resection and gives rise to tumor recurrence. The invasive phenotype also confers radioresistant and chemoresistant properties to the tumor cells; therefore, there is a critical need to develop new therapeutics that target drivers of GBM invasion. Amplification of EGFR is observed in over 50% of GBM tumors, of which half concurrently overexpress the variant EGFRvIII, and expression of both receptors confers a worse prognosis. EGFR and EGFRvIII cooperate to promote tumor progression and invasion, in part, through activation of the Stat signaling pathway. Here, it is reported that EGFRvIII activates Stat5 and GBM invasion by inducing the expression of a previously established mediator of glioma cell invasion and survival: fibroblast growth factor-inducible 14 (Fn14). EGFRvIII-mediated induction of Fn14 expression is Stat5 dependent and requires activation of Src, whereas EGFR regulation of Fn14 is dependent upon Src–MEK/ERK–Stat3 activation. Notably, treatment of EGFRvIII-expressing GBM cells with the FDA-approved Stat5 inhibitor pimozide blocked Stat5 phosphorylation, Fn14 expression, and cell migration and survival. Because EGFR inhibitors display limited therapeutic efficacy in GBM patients, the EGFRvIII–Stat5–Fn14 signaling pathway represents a node of vulnerability in the invasive GBM cell populations. Implications: Targeting critical effectors in the EGFRvIII–Stat5–Fn14 pathway may limit GBM tumor dispersion, mitigate therapeutic resistance, and increase survival. Mol Cancer Res; 16(7); 1185–95. ©2018 AACR.
Systematic review with meta‐analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis
Ma, Christopher , Guizzetti, Leonardo , Pai, Rish K. , Parker, Claire E. , Nguyen, Tran M , Khanna, Reena , Casteele, Niels Vande , D’Haens, Geert , Sandborn, William J. , Feagan, Brian G. , Ma, C , Guizzetti, L , Fedorak, R N , Pai, R K , Vande Casteele, N , D'Haens, G , Sandborn, W J , Feagan, B G , Jairath, V , Panaccione, Remo , Fedorak, Richard N. , Jairath, Vipul

Mayo Clinic

Alimentary Pharmacology & Therapeutics | April 26, 2018 | Volume: 47 | Issue: 12 | Pages: 1578-1596

10.1111/apt.14672 | PMID 29696670 Get It

Summary Background Regulatory requirements for claims of mucosal healing in ulcerative colitis ( UC ) will require demonstration of both endoscopic and histologic healing. Quantifying these rates is essential for future drug development. Aims To meta‐analyse endoscopic and histologic placebo response and remission rates in UC randomised controlled trials ( RCT s) and identify factors influencing these rates. Methods MEDLINE , EMBASE and the Cochrane Library were searched from inception to March 2017 for placebo‐controlled trials of pharmacological interventions for UC . Endoscopic and histologic placebo rates were pooled by random effects. Mixed effects univariable and multivariable meta‐regression was used to evaluate the influence of patient, intervention and trial‐related study‐level covariates on these rates. Results Fifty‐six induction (placebo n = 4171) and 8 maintenance trials (placebo n = 1011) were included. Pooled placebo endoscopic remission and response rates for induction trials were 23% [95 confidence interval ( CI ) 19‐28%] and 35% [95% CI 27‐42%] respectively, and 20% [95% CI 16‐24%] for maintenance of remission. The pooled histologic placebo remission rate was 14% [95% CI 8‐22%] for induction trials. High heterogeneity was observed for all outcomes ( I 2 56.2%‐88.3%). On multivariable meta‐regression, central endoscopy reading was associated with significantly lower endoscopic placebo remission rates (16% vs 25%; OR = 0.52, [95% CI 0.29‐0.92], P = 0.03). On univariable meta‐regression, higher histologic placebo remission was associated with concomitant corticosteroids ( OR = 1.17 [95% CI 1.08‐1.26], P < 0.0001, per 10% increase in corticosteroid use). Conclusions Placebo endoscopic and histologic rates range from 14% to 35% in UC RCT s but are highly heterogeneous. Outcome standardisation may reduce heterogeneity and is needed in this field.
The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance
Hersh, David S. , Harder, Bryan , Roos, Alison , Peng, Sen, Heath, Jonathan E., Legesse, Teklu, Kim, Anthony J. , Woodworth, Graeme F., Tran, Nhan L. , Winkles, Jeffrey A. , Harder, Bryan G., Winkles, Jeffrey A , Tran, Nhan L , Woodworth, Graeme F

Mayo Clinic

Neuro-Oncology | April 17, 2018 | Volume: 20 | Issue: 10 | Pages: 1321-1330

10.1093/neuonc/noy063 | PMID 29897522 Get It

Suspected thrombotic microangiopathy in a child with Epstein–Barr virus‐induced hemophagocytic lymphohistiocytosis
Cupit‐Link, Margaret C. , Kohorst, Mira A. , Tran, Cheryl L. , Bleesing, Jack , Galardy, Paul J. , Boyce, Thomas G. , Cupit-Link, Margaret , Cupit‐Link, Margaret C.

Mayo Clinic

Pediatric Blood & Cancer | February 7, 2018 | Volume: 65 | Issue: 6 | Pages: No page available

10.1002/pbc.27002 | PMID 29411928 Get It